Kuvan

Pre-clinicalTerminated

1 views this week 0 watching💤 Quiet

Interest: 15/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Jan 1, 2009 → Jan 1, 2010

NCT ID

NCT00827762

About Kuvan

Kuvan is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is terminated. This product is registered under clinical trial identifier NCT00827762. Target conditions include Phenylketonuria.

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria were approved

Approved (7) Terminated (1) Active (12)

❌SYNB1934v1 + PlaceboSynlogicPhase 3

🔄Kuvan®MerckPhase 3

✅Kuvan®MerckApproved

🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3

🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3

✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03864029	Pre-clinical	Completed	Oct 10, 2017	Jul 25, 2018	Tetrahydrobiopterin Deficiency
NCT02353312	Pre-clinical	Completed	Mar 1, 2015	Dec 1, 2018	Heart Failure
NCT01806051	Pre-clinical	Terminated	Mar 1, 2013	May 1, 2014	Phenylketonuria (PKU)
NCT01617070	Approved	Completed	May 1, 2012	Dec 1, 2014	Phenylketonuria (PKU)
NCT00827762	Pre-clinical	Terminated	Jan 1, 2009	Jan 1, 2010	Phenylketonuria
NCT00778206	Pre-clinical	Completed	Sep 1, 2008	Jan 29, 2021	Phenylketonuria

Competing Products

20 competing products in Phenylketonuria

See all competitors

Product	Company	Stage	Hype Score
mRNA-3210	Moderna	Phase 2	0
SYNB1934v1 + Placebo	Synlogic	Phase 3	22
SYNB1618 + Placebo	Synlogic	Phase 1/2	22
SYNB1618 + SYNB1934	Synlogic	Phase 2	25
Kuvan®	Merck	Phase 3	40
Kuvan®	Merck	Approved	43
SAR444836	Sanofi	Phase 1/2	36
rAvPAL-PEG	BioMarin Pharmaceutical	Phase 2	32
rAvPAL-PEG	BioMarin Pharmaceutical	Phase 2	32
Sapropterin (Kuvan)	BioMarin Pharmaceutical	Pre-clinical	23
BMN 165 (rAvPAL-PEG)	BioMarin Pharmaceutical	Phase 2	32
BMN 307	BioMarin Pharmaceutical	Phase 1/2	33
Sapropterin	BioMarin Pharmaceutical	Pre-clinical	23
Sapropterin dihydrochloride + Placebo	BioMarin Pharmaceutical	Phase 3	37
BMN165 20mg/day + BMN165 40mg/day + Placebo	BioMarin Pharmaceutical	Phase 3	37
sapropterin dihydrochloride	BioMarin Pharmaceutical	Phase 3	37
saproterin dihydrochloride	BioMarin Pharmaceutical	Approved	40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo	BioMarin Pharmaceutical	Phase 1	26
Pegvaliase	BioMarin Pharmaceutical	Pre-clinical	30
Pegvaliase	BioMarin Pharmaceutical	Pre-clinical	23